Efficacy News and Research

RSS

Duchenne Parent Project awards grant to AMT for DMD gene therapy

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy.

7 Mar 2011

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

FDA accepts Lundbeck's clobazam NDA for review

Lundbeck Inc. today announced the U.S. Food and Drug Administration has accepted for review a New Drug Application for the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome in patients two years and older.

5 Mar 2011

Biosante to purchase $25.1 million shares of common stock in registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $25.1 million of securities in a registered direct offering.

5 Mar 2011

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Medifocus Inc. is pleased to announce that two clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

5 Mar 2011

Researchers use qMRI to confirm effect of CS treatment in patients with OA

A group of Canadian researchers led by Prof. Jean-Pierre Pelletier, Head of the Osteoarthritis Research Unit at the University of Montreal Hospital Research Centre, published a clinical trial in which they confirm, for the first time using quantitative Magnetic Resonance Imaging, the disease modifying effects of chondroitin sulphate, a symptomatic slow acting drug for osteoarthritis.

5 Mar 2011

BNCT treatment proves effective in treating recurrent head, neck cancer

Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of a special carrier substance (phenylalanine), after which the tumour is irradiated with lowenergy neutrons.

5 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.

4 Mar 2011

ATS releases new report recommending research priorities in OSA treatment

The American Thoracic Society has released a new official report recommending research priorities in incorporating ambulatory management of adults with obstructive sleep apnea into healthcare systems.

4 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Immune Network Ltd. advises that Ukrainian company Ekomed LLC has agreed to collaborate with Immune Network and Immunitor for further clinical research of a tableted form of Ekomed's well-known immunomodulator herbal product Immunoxel/Dzherelo.

4 Mar 2011

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. FIRAZYR is the first and only treatment for acute Type I and Type II hereditary angioedema (HAE) attacks licensed for self-administration in Europe.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

CAS is an economically attractive alternative to endarterectomy for stroke patients

Researchers determined that carotid artery stenting with embolic protection is an economically attractive alternative to endarterectomy for patients at increased surgical risk.

3 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.

3 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Efficacy News and Research

Duchenne Parent Project awards grant to AMT for DMD gene therapy

Scientists identify regulatory T cells responsible for limiting immune response

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

FDA accepts Lundbeck's clobazam NDA for review

Biosante to purchase $25.1 million shares of common stock in registered direct offering

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Researchers use qMRI to confirm effect of CS treatment in patients with OA

BNCT treatment proves effective in treating recurrent head, neck cancer

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

ATS releases new report recommending research priorities in OSA treatment

BioSante vaccine increases median survival of resected pancreatic cancer patients

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

CAS is an economically attractive alternative to endarterectomy for stroke patients

Rockwell Medical fourth quarter net loss increases to $1.7 million

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News